Bonsity, Forteo, Forsteo (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Bonsity on 2002-11-26. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor. Forteo's patent is valid until 2025-03-25 (FDA).
|Indication||osteoporosis, postmenopausal osteoporosis|
|Drug Class||Peptides: parathyroid hormone related peptide|